EWTX Stock Analysis: Edgewise Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 4.372m USD | 12M Return: 242% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 52.2M
Qual. Beats: 0
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 5.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Edgewise Therapeutics (NASDAQ: EWTX) is a Boulder, Colorado-based biopharmaceutical company founded in 2017 that develops small-molecule therapies for muscle disorders. Its lead candidate, sevasemten, is an orally administered small molecule in Phase II clinical trials targeting dystrophinopathies such as Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). The pipeline also includes EDG-7500 in Phase I development for hypertrophic cardiomyopathy and EDG-15400 for heart failure with preserved ejection fraction (HFpEF), along with a broader set of precision medicine candidates aimed at genetically defined muscle conditions.
As a clinical-stage biotechnology company, Edgewise operates within a sector characterized by lengthy drug development timelines, significant R&D investment, and reliance on a small number of clinical-stage assets for future revenue. Its focus on small molecules-rather than biologics or gene therapies-positions it in the more traditional pharmaceutical modality space, where oral administration can offer advantages in patient compliance and manufacturing scalability, though success depends on navigating multi-year clinical and regulatory milestones before commercialization.
- Sevasemten Phase III ARCH trial readout in Duchenne muscular dystrophy approaching
- Cash runway narrows as clinical spending accelerates
- Competitor approvals from Sarepta and Capricor pressure Duchenne market share
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.29 > 0.02 and ΔFCF/TA -2.41 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.29 > 3% & CFO -148.5m > Net Income -176.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 22.61 > 1.5 & < 3 |
| Outstanding Shares: last quarter (107.1m) vs 12m ago 12.60% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.47%; Δ -0.47% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.94 (Total Current Assets 509.8m - Total Current Liabilities 22.5m) / Total Assets 518.5m |
| B: -1.15 (Retained Earnings -595.4m / Total Assets 518.5m) |
| C: -0.36 (EBIT TTM -176.0m / Avg Total Assets 486.5m) |
| D: 19.48 (Book Value of Equity 493.2m / Total Liabilities 25.3m) |
| Altman-Z'' = 20.44 = AAA |
As of July 08, 2026, the stock is trading at USD 43.13 with a total of 1,221,617 shares traded. Over the past week, the price has changed by +5.40%, over one month by +23.79%, over three months by +32.71% and over the past year by +242.03%.
Current recommended Stop Loss: 37.70 (which is 12.6% or 2.3 ATR below the current price).
Edgewise Therapeutics has received a consensus analysts rating of 4.30. Therefore, it is recommended to buy EWTX.
- StrongBuy: 5
- Buy: 3
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 48.2 | 11.7% |
P/B = 8.8635
Revenue TTM = 0.0 USD
EBIT TTM = -176.0m USD
EBITDA TTM = -176.0m USD
Long Term Debt = 2.78m USD (estimated: total debt 3.79m - short term 1.02m)
Short Term Debt = 1.02m USD (from shortTermDebt, last quarter)
Debt = 3.79m USD (from shortLongTermDebtTotal, last quarter) (leases 3.79m already included)
Net Debt = -495.8m USD (calculated: Debt 3.79m - CCE 499.6m)
Enterprise Value = 3.88b USD (4.37b + Debt 3.79m - CCE 499.6m)
Interest Coverage Ratio = unknown (Ebit TTM -176.0m / Interest Expense TTM 0.0)
EV/FCF = -26.06x (Enterprise Value 3.88b / FCF TTM -148.7m)
FCF Yield = -3.84% (FCF TTM -148.7m / Enterprise Value 3.88b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 2.27m) / Revenue TTM)
Tobins Q-Ratio = 7.47 (Enterprise Value 3.88b / Total Assets 518.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 3.79m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -139.0m (EBIT -176.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 22.61 (Total Current Assets 509.8m / Total Current Liabilities 22.5m)
Debt / Equity = 0.01 (Debt 3.79m / totalStockholderEquity, last quarter 493.2m)
Debt / EBITDA = 2.82 (negative EBITDA) (Net Debt -495.8m / EBITDA -176.0m)
Debt / FCF = 3.33 (negative FCF - burning cash) (Net Debt -495.8m / FCF TTM -148.7m)
Total Stockholder Equity = 540.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -36.18% (Net Income -176.0m / Total Assets 518.5m)
RoE = -32.55% (Net Income TTM -176.0m / Total Stockholder Equity 540.8m)
RoCE = -32.38% (EBIT -176.0m / Capital Employed (Equity 540.8m + L.T.Debt 2.78m))
RoIC = -27.98% (negative operating profit) (NOPAT -139.0m / Invested Capital 497.0m)
WACC = 11.62% (E(4.37b)/V(4.38b) * Re(11.63%) + D(3.79m)/V(4.38b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.63% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.22 | Cagr: 25.05%
[DCF] Fair Price = unknown (Cash Flow -148.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.47 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.48 | Chg30d=+0.83% | Revisions=-17% | Analysts=11
EPS next Quarter (2026-09-30): EPS=2.47 | Chg30d=+574.90% | Revisions=+12% | Analysts=7
EPS current Year (2026-12-31): EPS=1.28 | Chg30d=+162.80% | Revisions=-12% | GrowthEPS=+178.3% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.42 | Chg30d=+38.91% | Revisions=-12% | GrowthEPS=-211.6% | GrowthRev=-74.9%
[Analyst] Revisions Ratio: -10% (up=8, down=10)